INVESTING IN PASSIONATE FOUNDERS REVOLUTIONIZING MEDICAL SOLUTIONS

At Olympus Innovation Ventures we invest in customer driven solutions in medical devices, diagnostics and digital health that complement or extend our market leading endoscopic solutions.

Group Meeting

WE HELP INNOVATIVE STARTUPS CREATE COMPETITIVE ADVANTAGE THROUGH ADVICE, PROMOTION AND PARTNERSHIP WITH OLYMPUS.

At OIV we pride ourselves on our ability to bring 100+ years of medtech leadership to aid founders as they navigate clinical validation, regulatory approval, commercial distribution in global markets and so much more. Entrepreneurs benefit from our technical and clinical expertise, scale and fantastic relationships with healthcare systems across the globe.

Andre Roggan

Andre Roggan
Chief Technology Officer

Gabriela Kaynor

Gabriela Kaynor
Chief Strategy Officer

Tetsu Mori

Tetsu Mori
Senior Vice President,
Strategy Excellence and Solutions

Tatsuya Izumi

Tatsuya Izumi
Chief Financial Officer

Townsend Goddard

Townsend Goddard
Senior Vice President,
Global Head, Business Development

Townsend Goddard

John de Csepel, MD
Chief Medical Officer
Global Head, Medical & Scientific Affairs

Touchdown Ventures

Our Partner

Touchdown Ventures helps manage Olympus Innovation Ventures with a dedicated corporate venture capital team, partnering on all aspects of operating the fund. Touchdown employs 50+ investment professionals and operates CVC funds for more than 15 corporations.

How We Invest

Clinical Areas

Clinical Areas
Gastroenterology, Respiratory, Urology, ENT, Gynecology, General Surgery

Stage Focus

Stage Focus
Seed through Growth

Check Size

Check Size
USD $500K - $5M

Geographical Focus

Geographical Focus
Global

Investments Per year

Investments Per year
Three to Five

Round

Round
Lead or join funding rounds

Related News, Events, and Resources

Related Blog Post

Illuminating Cancer Cells During Surgery: A Worthy Olympus Investment

Learn More
Related Blog Post

When Little Things are a Big Deal: Olympus’ Investment in Eximis Aims to Keep Incisions Small

Learn More
Alimetry

AI Integrated Wearables for Gut Health Diagnosis: Olympus Innovation Ventures Invests in Alimetry

Learn More

Our Portfolio

EXIMIS
Eximis
MIS specimen segmentation and removal solution with integrated electrified wires to slice tissue for safe and easy removal.
Neuspera Medical
Neuspera Medical
A neuromodulation company pioneering an ultra-miniaturized sacral neuromodulation implant for treatment of symptoms of overactive bladder.
ON TARGET LABORATORIES
On Target Labs
Intraoperative molecular imaging agents that bind to cancerous tissue and fluoresce under near infrared light.
Universal Diagnostics
Universal Diagnostics
A biotech company dedicated to transferring colorectal cancer into a treatable disease by detecting it early.
Virgo
Virgo
Virgo provides GIs with one video endoscopy solution for recording, reading, and analysis, and accelerates clinical trial recruitment through AI.

Contact Us

To reach Olympus Innovation Ventures, LLC, please submit the form below.

  • Nothing you submit is confidential or proprietary. OIV will not (and does not have a duty to) treat the information as confidential or proprietary and will assume it is publicly available.
  • OIV will not treat any information as confidential or proprietary unless you and OIV enter into and sign a written confidential disclosure agreement. That agreement will include your and OIV’s obligations with respect to the treatment of such information.
  • OIV may receive submissions from other third parties that are the same as or substantially similar to your submission.
  • OIV and its affiliates may currently be conducting or considering conducting research and development and developing and registering intellectual property that is the same as or substantially similar to your submission. OIV and its affiliates may also begin conducting those projects in the future, even after receipt of your submission. You have no rights to OIV’s and its affiliates’ developments.
  • OIV is under no obligation to enter into a relationship with you. If the parties do decide to enter into a formal relationship, they will do so pursuant to a signed, written definitive agreement. That agreement will include your and OIV’s rights, duties and obligations with respect to the relationship.
  • You have the legal authority to make the submission and provide the information included in such submission. You also have the authority to discuss the information with OIV. If you are submitting or discussing the information on behalf of a company, corporation, partnership or other legal entity, that entity has authorized you to do so.
  • Your submission will be reviewed and considered in accordance with OIV’s policies and procedures.

Investor Information